Male breast cancer (MBC) is a rare and understudied disease compared with female BC. About 15% of MBCs are associated with germline mutation in BC susceptibility genes, mainly BRCA1/2 and PALB2. Hereditary MBCs are likely to represent a subgroup of tumors with a peculiar phenotype. Here, we performed a whole transcriptome analysis of MBCs characterized for germline mutations in the most relevant BC susceptibility genes in order to identify molecular subtypes with clinical relevance. A series of 63 MBCs, including 16 BRCA2, 6 BRCA1, 2 PALB2, 1 RAD50, and 1 RAD51D germline-mutated cases, was analyzed by RNA-sequencing. Differential expression and hierarchical clustering analyses were performed. Module signatures associated with central biological processes involved in breast cancer pathogenesis were also examined. Different transcriptome profiles for genes mainly involved in the cell cycle, DNA damage, and DNA repair pathways emerged between MBCs with and without germline mutations. Unsupervised clustering analysis revealed two distinct subgroups, one of which was characterized by a higher expression of immune response genes, high scores of gene-expression signatures suggestive of aggressive behavior, and worse overall survival. Our results suggest that transcriptome matched with germline profiling may be a valuable approach for the identification and characterization of MBC subtypes with possible relevance in the clinical setting.

Transcriptome of male breast cancer matched with germline profiling reveals novel molecular subtypes with possible clinical relevance / Zelli, V.; Silvestri, V.; Valentini, V.; Bucalo, A.; Rizzolo, P.; Zanna, I.; Bianchi, S.; Coppa, A.; Giannini, G.; Cortesi, L.; Calistri, D.; Tibiletti, M. G.; Fox, S. B.; Kconfab, ; Palli, D.; Ottini, L.. - In: CANCERS. - ISSN 2072-6694. - 13:18(2021), pp. 4515-4529. [10.3390/cancers13184515]

Transcriptome of male breast cancer matched with germline profiling reveals novel molecular subtypes with possible clinical relevance

Cortesi L.;
2021

Abstract

Male breast cancer (MBC) is a rare and understudied disease compared with female BC. About 15% of MBCs are associated with germline mutation in BC susceptibility genes, mainly BRCA1/2 and PALB2. Hereditary MBCs are likely to represent a subgroup of tumors with a peculiar phenotype. Here, we performed a whole transcriptome analysis of MBCs characterized for germline mutations in the most relevant BC susceptibility genes in order to identify molecular subtypes with clinical relevance. A series of 63 MBCs, including 16 BRCA2, 6 BRCA1, 2 PALB2, 1 RAD50, and 1 RAD51D germline-mutated cases, was analyzed by RNA-sequencing. Differential expression and hierarchical clustering analyses were performed. Module signatures associated with central biological processes involved in breast cancer pathogenesis were also examined. Different transcriptome profiles for genes mainly involved in the cell cycle, DNA damage, and DNA repair pathways emerged between MBCs with and without germline mutations. Unsupervised clustering analysis revealed two distinct subgroups, one of which was characterized by a higher expression of immune response genes, high scores of gene-expression signatures suggestive of aggressive behavior, and worse overall survival. Our results suggest that transcriptome matched with germline profiling may be a valuable approach for the identification and characterization of MBC subtypes with possible relevance in the clinical setting.
2021
13
18
4515
4529
Transcriptome of male breast cancer matched with germline profiling reveals novel molecular subtypes with possible clinical relevance / Zelli, V.; Silvestri, V.; Valentini, V.; Bucalo, A.; Rizzolo, P.; Zanna, I.; Bianchi, S.; Coppa, A.; Giannini, G.; Cortesi, L.; Calistri, D.; Tibiletti, M. G.; Fox, S. B.; Kconfab, ; Palli, D.; Ottini, L.. - In: CANCERS. - ISSN 2072-6694. - 13:18(2021), pp. 4515-4529. [10.3390/cancers13184515]
Zelli, V.; Silvestri, V.; Valentini, V.; Bucalo, A.; Rizzolo, P.; Zanna, I.; Bianchi, S.; Coppa, A.; Giannini, G.; Cortesi, L.; Calistri, D.; Tibilett...espandi
File in questo prodotto:
File Dimensione Formato  
cancers-13-04515.pdf

Open access

Tipologia: VOR - Versione pubblicata dall'editore
Dimensione 1.07 MB
Formato Adobe PDF
1.07 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1404064
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? ND
social impact